Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Treating BCG-unresponsive bladder cancer

Wassim Kassouf • 15 Feb 2020
GU Cancers 2020
Bladder Cancer Genitourinary Cancer BCG Docetaxel Gemcitabine Pembrolizumab

Wassim Kassouf, FRCS, MD, McGill University Health Centre, Montreal, Canada, outlines the options for BCG unresponsive urothelial carcinoma. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Wassim Kassouf

Radiosensitization in bladder cancer
1:19
Radiosensitization in bladder cancer
Wassim Kassouf • 15 Feb 2020

Related Videos

Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
3:04
Enzalutamide outcomes & duration predictors in mHSPC: ARCHES post hoc analyses
Andrew Armstrong • 3 Jun 2026
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
2:24
Chemo-IO in neuroendocrine or aggressive variant metastatic prostate cancer
Andrew Armstrong • 3 Jun 2026
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
2:10
Treatment sequencing after EV plus pembrolizumab in metastatic bladder cancer
Tian Zhang • 1 Jun 2026
Highlights in ADCs for bladder cancer at ASCO 2026
1:29
Highlights in ADCs for bladder cancer at ASCO 2026
Tian Zhang • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals